Pharmacoeconomic analysis of ranibizumab and aflibercept for treatment of diabetic macular edema

Diabetes mellitus (DM) is a widespread, severe disease that has outpaced many infectious and non-infectious diseases in terms of both incidence increases and economic burden in most developed countries. In addition to the direct threat to the health and well-being of patients, DM is associated with many severe complications. Among the most significant late complications of DM are diabetic retinopathy (DR) and diabetic macular edema (DME) which can lead to slow, persistent vision loss up to blindness. Significant progress in treating DME has been obtained after the role of vascular endothelium growth factor (VEGF) in the disease’s pathophysiology became more understood, with several powerful clinical options emerging as result. Among the anti-VEGF drugs that have proven themselves well in clinical trials and practice with regards to treating DME are ranibizumab and aflibercept. Since there is currently relatively little understanding of their comparative pharmacoeconomic performance within context of Russian healthcare, the current pharmacoeconomic research (PHe) effort was undertaken. Aim. To perform comparative PHe analysis of ranibizumab and aflibercept for treatment of patients with DME in Russian Federation (RF). Methodology. A Markov model with 3 month long cycles, simulating the changes in patient’s vision acuity was designed for this research effort. For each of the compared therapeutic alternative a simulated group of 1000 DME patients was constructed. The PHe analysis was performed from the point of view of Russian healthcare system within context of Mandatory Medical Insurance system and also from point of view of Russian budget as whole. Randomized controlled clinical trials investigating safety and efficacy of analyzed drugs were used as source of efficacy and safety data. Number of patients who avoided stage IV vision loss (blindness) was used as efficacy criterion. Time horizon of PHe analysis was set at 3 years. Costs were accounted based on existing treatment standards, and literature sources were used to link quality of life and vision acuity and then register QALY for various model states. Modelling results were used to carry out cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and budget impact analysis (BIA). Two single-factor sensitivity analyses (SA) were used to ensure the results are robust to changes in market situation, and an additional analysis was undertaken to test for effects of choice of eye being treated (better seeing or worse seeing). Results. CEA indicated that ranibizumab administered using Pro Re Nata (PRN) regimen has best cost-efficacy, with lowest CER of 1 264 rub. Ranibizumab administered in Treat and Extend (T&E) regimen and aflibercept had higher CERs and thus inferior cost-efficacy (1 403 rub and 1667 rub respectively). The advantage of ranibizumab PRN extended to CUA, in which CUR was 554 rub for ranibizumab PRN, 616 rub for ranibizumab T&E and 729 rub for aflibercept. BIA performed per 100 000 population (accounted for prevalence of DM and DME epidemiology) has found that use of ranibizumab PRN instead of aflibercept could result in budget burden reduction of more than 17 million rubles per 3 years. All SA have confirmed result robustness. Conclusion. These results indicate that ranibizumab demonstrates favorable pharmacoeconomic properties and its further introduction into Russian clinical practice would allow to increase the efficacy of healthcare resource utilization in the RF.

ранибизумаб, афлиберцепт, диабетическая ретинопатия, диабетический макулярный отёк, диабет, Pro Re Nata, Treat and Extend, PRN, T&E, фармакоэкономика, анализ затраты-эффективность, анализ затраты-полезность, анализ влияния на бюджет, DME, diabetes mellitus, aflibercept, ranibizumab, Pro Re Nata, Treat and Extend, PRN, T&E, macular edema, pharmacoeconomics, cost-effectiveness analysis, cost-utility analysis, budget impact analysis

1. Aiello L.P., Avery R.L., Arrigg P.G. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994; 331: 22: 1480-7.

2. Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. The New England Journal of Medicine. 2012; 366: 13: 1227-1239.

3. Bakshi N.K. Update on the VIVID-DME and VISTA-DME trials. Ophthalmol Sci Update. 2014. [Электронный ресурс]. http://www.ophthalmologyupdate.ca/crus/230-015%206-pages%20English.pdf (дата обращения 29.05.2017).

4. Bressler N.M., Chang T.S., Su?er I.J. MARINA and ANCHOR Research Groups Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010; 117 (4): 747.e-756.

5. Campochiaro P.A., Sophie R., Pearlman J. et al. RETAIN Study Group Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN Study. Ophthalmology. 2014; 121: 209-219.

6. Chaturvedi N., Sjolie A.K., Stephenson J.M. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: the EUCLID Study Group EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet. 1998; 35: 28-31.

7. Ciulla T.A., Amador A.G., Zinman B. Diabetic retinopathy and diabetic macular edema: Pathophysiology, screening, and novel therapies. Diabetes Care. 2003; 26: 2653-2664.

8. Colin A. McCannel, et al. Updated Guidelines for Intravitreal Injection. Review of Ophthalmology. 2015; [Электронный ресурс]. URL: https://www.reviewofophthalmology.com/content/d/retinal_insider/c/55627/. (дата обращения 12.07.2017).

9. Czoski-Murray C., Carlton J., Brazier J., Young T., Papo N.L., Kang H.K. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009; 12: 793-799.

10. Deák G.G., Bolz M., Ritter M. et al. Diabetic Retinopathy Research Group Vienna. A systematic correlation between morphology and functional alterations in diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2010; 51: 12: 6710-6714.

11. Fong D.S. Changing Times for the Management of Diabetic Retinopathy. Surv. Ophthalmol. 2002; 47: 238-245.

12. Jonas J.B., Kreissig I., Sofker A., Degenring R.F. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch. Ophthalmol. 2003; 121: 57-61.

13. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye and Vision. 2015; 2: 17.

14. Kohner E.M., Porta M. Diabetic retinopathy: preventing blindness in the 1990’s. Diabetologia. 1991; 34: 11: 844-845.

15. Korobelnik J.F., Do D.V., Schmidt-Erfurth U. et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014; 121 (11): 2247-2254.

16. Martidis A., Duker J.S., Greenberg P.B. Intravitreal triamcinolone for refractory diabetic macular edema. Am. J. Ophthalmol. 2002; 109: 920-927.

17. Mitchell P., Bandello F., Schmidt-Erfurth U. et al. RESTORE Study Group The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118 (4): 615-625.

18. Nakamura S., Iwasaki N., Funatsu H., Kitano S., Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009; 247: 1: 21-26.

19. National Institute for Health and Care Excellence Aflibercept Solution for Injection for Treating Wet Age-Related Macular Degeneration [TA294] 2013 [Электронный ресурс]. URL: http://www.nice.org.uk/guidance/ta294. (дата обращения 02.06.2017).

20. Pruente C., Group R.S. Efficacy and safety of ranibizumab in two treat-and-extend versus pro-re-nata regimes in patients with visual impairment due to diabetic macular edema: 24-month results of RETAIN study. Invest Ophthalmol Vis Sci. 2014; 55 E-Abstract 1700.

21. Prünte C., Fajnkuchen F., Mahmood S. et al. Ranibizumab 0.5?mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 2016; 100: 787-95.

22. Regnier S., Malcolm W., Allen F., Wright J., Bezlyak V. Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis. PLoS One. 2014; 9 (7): e102309.

23. Rotsos T.G., Moschos M.M. Cystoid macular edema. Clin. Ophthalmol. 2008; 2: 4: 919-930.

24. Sakata K., Funatsu H., Harino S. Relationship of macular microcirculation and retinal thickness with visual acuity in diabetic macular edema. Ophthalmology. 2007; 114: 11: 2061-2069.

25. Schmidt-Erfurth U., Lang G.E., Holz F.G. et al. RESTORE Extension Study Group Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014; 121 (5): 1045-1053.

26. Schwartz R. Biological Modeling and Simulation: A Survey of Practical Models, Algorithms and Numerical Methods 2008. The MIT Press.

27. WHO Global status report on noncommunicable diseases 2014. Geneva, World Health Organization [Электронный ресурс]. http://www.era-edta.org/ekha/WHO_Global_Status_Report_on_NCDs_2014.pdf (дата обращения: 05.06.2017).

28. Zhang P., Gregg E. Global economic burden of diabetes and its implications. Lancet Diabetes Endocrinol. 2017 Jun; 5 (6): 404-405.

29. Аналитическая информация, IMS Россия, 2017 г. [Электронный ресурс]. URL: http://www.ims.ru/.

30. Аналитическая система БД «Курсор» 2017 г. [Электронный ресурс]. URL: http://cursor-is.ru/ru/

31. Астахов Ю.С., Шадричев Ф.Е., Лисочкина А.Б. Диабетическая ретинопатия // Офтальмология: Клинические рекомендации. Изд. 2-е, испр. и доп. / Под ред. Л.К. Мошетовой, А.П. Нестерова, Е.А. Егорова. М.: “ГОЭТАР-Медиа” 2009; 186-217.

32. Астахов Ю.С., Шадричев Ф.Е., Лисочкина А.Б. Диабетическая ретинопатия (тактика ведения пациентов). Клиническая офтальмология. 2004; 5: 2: 85-88.

33. Балашевич Л.И., Измайлов А.С. Диабетическая офтальмопатия. СПб.: Человек. 2012; 336.

34. Белоусов Ю.Б., Комарова В.П., Белоусов Д.Ю. Учебное пособие «Основы фармакоэкономических исследований», М. 2000 г. Национальный фонд содействия научным и клиническим исследованиям при РГМУ

35. Глава 27 Медико-социальная экспертиза и реабилитация лиц с заболеваниями и повреждениями органа зрения. / «Глазные болезни. Основы офтальмологии: Учебник» / под ред. В.Г. Копаевой. М.: ОАО «Издательство «Медицина», 2012; 552-557.

36. Государственный реестр предельных отпускных цен. [Электронный ресурс] http://grls.rosminzdrav.ru/pricelims.aspx.

37. Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития. «Сахарный диабет». 2015; 18 (3): 5-22.

38. Информационный сервис «aptekamos.ru» [Электронный ресурс]. URL: http://aptekamos.ru/ (дата обращения: 08.04.2016).

39. Инструкция по применению препарата Ранибизумаб на Сайте Государственного реестра лекарственных средств. [Электронный ресурс] URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ced94c65-f7e8-4c3b-81b2-ab92c3a11a69&t= (дата обращения: 01.06.2017).

40. Инструкция по применению препарата Афлиберцепт на Сайте Государственного реестра лекарственных средств. [Электронный ресурс] URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0bfffb6c-97b4-486e-82df-5f7b43cc579b&t= (дата обращения: 01.06.2017).

41. Мкртумян А.Ф. Лечение сахарного диабета и его осложнений. РМЖ. 2002; 10: 17.

42. Он-лайн прайс-листы медицинских услуг ФГАУ «МНТК «Микрохирургия глаза» им. акад. С.Н. Федорова» Минздрава РФ URL: http://mntk.ru/patients/prices/ (дата обращения 15.05.2017)

43. Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Приказ Минздрава РФ от 27.05.2002 № 163 [Электронный ресурс]. URL: http://www.healtheconomics.ru/index.php?option=com_content&view=article&id=300:-q-q&catid=55:2009-05-29-19-56-44&Itemid=104.

44. Омельяновский В.В., Авксентьева М.В., Сура М.В. и др. «Методические рекомендации по проведению сравнительной клинико-экономической оценки лекарственного препарата». М.: 2016. [Электронный ресурс]. URL: https://rosmedex.ru/wp-content/uploads/2016/12/MR-KE%60I-23.12.2016.pdf

45. Он-лайн ресурс ООО «Московская Глазная Клиника», раздел «интравитреальная инъекция» URL: https://mgkl.ru/uslugi/intravitrealnaya-inektsiya (дата обращения 19.07.2017)

46. Приказ Минздрава России от 24.12.2012 N 1492н «Об утверждении стандарта первичной медико-санитарной помощи при диабетической ретинопатии и диабетическом макулярном отеке» (Зарегистрировано в Минюсте России 19.03.2013 N 27776)

47. Сунцов Ю.И., Дедов И.И. Государственный регистр - основная информационная система расчетов экономических затрат государства на сахарный диабет и прогнозирование. Сахарный диабет 2005; (2): 2-5.

48. Тарифы на медицинские услуги Московского городского фонда ОМС, введённые в действие в 29.12.2016 [Электронный ресурс]. URL: http://www.mgfoms.ru.

49. Федеральный закон от 1 декабря 2014 г. N 384-ФЗ «О федеральном бюджете на 2015 год и на плановый период 2016 и 2017 годов»

50. Хабриев Р.У., Куликов А.Ю., Аринина Е.Е. Методологические основы фармакоэкономического анализа. М.: 2011.

51. Ягудина Р.И., Куликов А.Ю., Метелкин И.А. Методология анализа «затраты-эффективность» при проведении фармакоэкономических исследований. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2012; 4: 3-8.